Allianz Asset Management Gmb H Arvinas, Inc. Transaction History

Allianz Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$14.19 - $42.33 $95,073 - $283,611	6,700 New	6,700 $275,000
Q3 2022 Nov 08, 2022	SELL	$41.87 - $57.99 $1.35 Million - $1.87 Million	-32,330 Reduced 74.1%	11,300 $503,000
Q2 2022 Aug 12, 2022	BUY	$36.01 - $74.24 $232,804 - $479,961	6,465 Added 17.4%	43,630 $1.84 Million
Q1 2022 May 13, 2022	BUY	$60.27 - $81.57 $389,103 - $526,615	6,456 Added 21.02%	37,165 $2.5 Million
Q4 2021 Feb 11, 2022	BUY	$65.85 - $96.21 $267,351 - $390,612	4,060 Added 15.24%	30,709 $2.51 Million
Q3 2021 Nov 10, 2021	BUY	$73.2 - $107.87 $1,464 - $2,157	20 Added 0.08%	26,649 $2.19 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $120 - $168	2 Added 0.01%	26,629 $2.05 Million
Q1 2021 May 13, 2021	BUY	$58.19 - $91.37 $212,800 - $334,140	3,657 Added 15.92%	26,627 $1.76 Million
Q4 2020 Feb 16, 2021	BUY	$20.19 - $84.93 $463,764 - $1.95 Million	22,970 New	22,970 $1.95 Million

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.